Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | LCAT | P04180 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245408 | 0.82 | CNR2 (0.44) | CNR2HRH3ALDH1A1CNR1MYC | |
| SCHEMBL25840185 | 0.75 | HRH3 (0.47) | HRH3CYP1A2CYP2D6GPR119KDM4E | |
| SCHEMBL20797611 | 0.75 | KCNJ1 (0.46) | CNR2KDM4EL3MBTL1ALDH1A1CNR1 | |
| SCHEMBL20797345 | 0.75 | KCNJ1 (0.46) | CNR2KDM4EL3MBTL1ALDH1A1CNR1 | |
| SCHEMBL20810916 | 0.75 | KCNJ1 (0.46) | CNR2KDM4EL3MBTL1ALDH1A1CNR1 | |
| SCHEMBL20797535 | 0.75 | KCNJ1 (0.46) | CNR2KDM4EL3MBTL1ALDH1A1CNR1 | |
| SCHEMBL12141112 | 0.72 | KMT2A (0.49) | HRH3KDM4EALDH1A1RAB9A | |
| SCHEMBL13662112 | 0.72 | KMT2A (0.49) | HRH3KDM4EALDH1A1RAB9A | |
| SCHEMBL21097708 | 0.72 | CKS1B (0.47) | HRH3CYP1A2CYP2D6GPR119LCAT | |
| SCHEMBL10331958 | 0.72 | LCAT (0.47) | HRH3CYP1A2CYP2D6GPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | CNR2 3169/4885HRH3 1065/4885CYP1A2 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.